Health & Fitness
Tue, January 3, 2012
NEWARK, Del.--([ BUSINESS WIRE ])--[ SDIX ]a" (NASDAQ: SDIX), today announced the publication of a comparative, in-depth study characterizing the strengths of its innovative DNA-immunization based Genomic Antibody Technologya", or GATa". The article provides data that shows the significant advantage of SDIXas antibody technology versus current conventional approaches.
"We believe SDIX Genomic Antibody Technology provides these researchers with a significantly higher likelihood of successfully finding antibodies for their intended purposes. Our study demonstrates that these advantages become even more apparent for complex and demanding ultra-high sensitivity assays."
The study was based upon antibodies generated with both SDIX GAT and conventional peptide immunization. Three different peptide-based antibodies and three different GAT-based antibodies each were raised against ten exemplary, well characterized targets. Analysis of the resulting sixty antibodies in a range of different assay formats, including Western Blot, ELISA, and immunohistochemistry, demonstrated that the antibodies produced using the SDIX Genomic Antibody Technology broadly outperformed peptide-based antibodies by a large, statistically significant margin.
"Target specific antibodies are essential elements for advanced diagnostic and therapeutics, yet their development with current technologies is challenging and has resulted in limited success,a commented Dr. Klaus Lindpaintner, CSO, and VP of R&D at SDIX. "We believe SDIX Genomic Antibody Technology provides these researchers with a significantly higher likelihood of successfully finding antibodies for their intended purposes. Our study demonstrates that these advantages become even more apparent for complex and demanding ultra-high sensitivity assays."
"Currently there is a significant research effort to develop monoclonal antibody therapeutics to treat a range of diseases including cancer, inflammatory and autoimmune disorders,a continued Dr. Klaus Lindpaintner. aThe SDIX Genomic Antibody Technology described in this paper is the same technology the company has been applying to the development of monoclonal antibodies.a
aMajor pharmaceutical companies are now devoting significant portions of their R&D pipelines to the development of monoclonal antibody therapeutics, whose current U.S. sales exceed $30 billion annually. Importantly, effective monoclonal antibody therapeutics require the development of highly target specific antibodies,a noted Mike Young, VP Sales and Marketing. aThe application of SDIXas Genomic Antibody Technology has the potential to significantly enhance the pharmaceutical and biotechnology industriesa ability to develop novel monoclonal antibodies that are designed to achieve superior results in treating serious diseases.a
For a link to the study, aImpact of Immunization Technology and Assay Application on Antibody Performancea, please visit the SDIX website.
About SDIX ([ www.sdix.com ])
SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIXas technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results.
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like aanticipatea, acoulda, aenablea, aestimatea, aintenda, aexpecta, abelievea, apotentiala, awilla, ashoulda, aprojecta, aplan,a adesigneda and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
